Zevin Asset Management LLC lowered its holdings in GlaxoSmithKline plc (NYSE:GSK) by 16.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,701 shares of the pharmaceutical company’s stock after selling 4,340 shares during the quarter. Zevin Asset Management LLC’s holdings in GlaxoSmithKline were worth $969,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marshall Wace North America L.P. acquired a new stake in shares of GlaxoSmithKline in the 1st quarter worth about $62,000. Thomasville National Bank increased its stake in GlaxoSmithKline by 4.4% during the second quarter. Thomasville National Bank now owns 42,060 shares of the pharmaceutical company’s stock worth $1,683,000 after purchasing an additional 1,770 shares during the period. Private Trust Co. NA increased its stake in GlaxoSmithKline by 29.5% during the second quarter. Private Trust Co. NA now owns 9,238 shares of the pharmaceutical company’s stock worth $369,000 after purchasing an additional 2,104 shares during the period. South Texas Money Management Ltd. increased its stake in GlaxoSmithKline by 1.1% during the second quarter. South Texas Money Management Ltd. now owns 762,940 shares of the pharmaceutical company’s stock worth $30,533,000 after purchasing an additional 8,244 shares during the period. Finally, Signature Wealth Management Group increased its stake in GlaxoSmithKline by 1.0% during the second quarter. Signature Wealth Management Group now owns 80,601 shares of the pharmaceutical company’s stock worth $3,293,000 after purchasing an additional 796 shares during the period. Hedge funds and other institutional investors own 11.19% of the company’s stock.
A number of equities analysts have recently commented on the company. Cantor Fitzgerald raised GlaxoSmithKline from a “hold” rating to a “buy” rating in a research report on Friday, October 11th. New Street Research raised GlaxoSmithKline from a “reduce” rating to a “hold” rating in a report on Wednesday, October 16th. Goldman Sachs Group reissued a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, October 30th. Societe Generale raised GlaxoSmithKline from a “sell” rating to a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $41.79.
Shares of GlaxoSmithKline stock traded up $0.21 during trading hours on Friday, hitting $44.42. 1,985,586 shares of the company were exchanged, compared to its average volume of 2,550,711. GlaxoSmithKline plc has a 1 year low of $36.41 and a 1 year high of $46.01. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 1.38. The business has a 50-day moving average of $42.96 and a 200-day moving average of $41.12. The stock has a market capitalization of $110.42 billion, a price-to-earnings ratio of 14.06, a P/E/G ratio of 3.03 and a beta of 0.70.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, October 30th. The pharmaceutical company reported $0.95 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. The business had revenue of $11.57 billion during the quarter, compared to analysts’ expectations of $11.34 billion. As a group, research analysts anticipate that GlaxoSmithKline plc will post 3.08 earnings per share for the current fiscal year.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline acquired 357,142 shares of the business’s stock in a transaction on Friday, October 18th. The stock was purchased at an average price of $28.00 per share, for a total transaction of $9,999,976.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.00% of the stock is owned by corporate insiders.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Golden Cross
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.